By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) - Miraculins said today that Alere has secured a second exclusive option period on Miraculins' preeclampsia technology and will provide Miraculins a non-refundable fee. Under the terms of the original agreement signed two years ago, Alere is working towards the goal of commercializing Miraculins' preeclampsia technology for worldwide distribution.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.